bosentan anhydrous has been researched along with macitentan in 39 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 29 (74.36) | 24.3611 |
| 2020's | 10 (25.64) | 2.80 |
| Authors | Studies |
|---|---|
| Binkert, C; Bolli, MH; Boss, C; Buchmann, S; Bur, D; Clozel, M; Fischli, W; Hess, P; Iglarz, M; Meyer, S; Rein, J; Rey, M; Treiber, A; Weller, T | 1 |
| Bolli, MH; Boss, C; Gatfield, J | 1 |
| Fu, L; Gao, F; Huang, S; Zhang, L; Zhao, S; Zhen, Y; Zhou, X | 1 |
| Clozel, M; Gatfield, J; Mueller Grandjean, C; Nayler, O; Sasse, T | 1 |
| Humbert, M; Jardim, C; Souza, R | 1 |
| Brouwer, KR; Gillies, H; Hao, J; Hubert, C; Lepist, EI; Ray, AS; Smith, W; St Claire, RL | 1 |
| Bortolamiol, C; Bossu, A; Clozel, M; Hess, P; Iglarz, M; Rey, M; Wanner, D | 1 |
| Watanabe, H | 1 |
| Äänismaa, P; de Kanter, R; Delahaye, S; Hess, P; Sidharta, P; Treher, M; Treiber, A | 1 |
| Davenport, AP; Maguire, JJ | 1 |
| Braine, CE; Howell, GR; John, SW; Macalinao, DG; MacNicoll, KH; Soto, I; Sousa, GL | 1 |
| Bolli, MH; Bur, D; Gatfield, J; Mueller Grandjean, C; Nayler, O | 1 |
| Alessandri, E; Brizzolara, R; Cutolo, M; Montagna, P; Pizzorni, C; Smith, V; Soldano, S; Sulli, A; Tavilla, PP; Villaggio, B | 1 |
| Dingemanse, J; Krähenbühl, S; Sidharta, PN | 1 |
| Aversa, M; Granton, J; Porter, S | 1 |
| Bauer, Y; Bortolamiol, C; Cattaneo, C; Clozel, M; Delahaye, S; Freti, D; Hadana, H; Hess, P; Iglarz, M; Landskroner, K; Nayler, O; Renault, B; Rey, M; Schläpfer, M; Steiner, P; Studer, R; Vercauteren, M; Vezzali, E; Wanner, D; Weber, E; Whitby, BR | 1 |
| Canestaro, WJ; Devine, BE; Forrester, SH; Ho, L; Raghu, G | 1 |
| Chirico, C; Corallo, C; Cutolo, M; Giordano, N; Kahaleh, B; Montella, A; Nuti, R; Pecetti, G; Soldano, S | 1 |
| Blok, IM; Bouma, BJ; Mulder, BJM; van Dijk, APJ; van Riel, ACMJ | 1 |
| Angus, JA; Hughes, RJA; Soeding, PF; Wright, CE | 1 |
| Benjamin, N; Burhenne, J; Egenlauf, B; Enderle, Y; Fischer, C; Grünig, E; Haefeli, WE; Harutyunova, S; Huppertz, A; Klose, H; Ohnesorge, J | 1 |
| Alehan, D; Aykan, HH; Aypar, E; Ertugrul, İ; Karagöz, T | 1 |
| Borges, FT; Caires, A; Castino, B; Fernandes, GS; Fernandes, SM; Fonseca, CD; Leme, AM; Pessoa, EA; Schor, N; Vattimo, MF | 1 |
| Behr, J; Bonella, F; Costabel, U; Geißler, K; Günther, A; Koschel, D; Kreuter, M; Müller-Quernheim, J; Prasse, A; Schönfeld, N; Sitter, H | 1 |
| Coghlan, C; Coghlan, JG; Dawson, A; Reddecliffe, S; Schreiber, BE | 1 |
| Dweik, RA; Heresi, GA; Highland, KB; Love, TE; Tonelli, AR | 1 |
| Kuang, HY; Li, Q; Lu, TW; Wu, YH; Yi, QJ | 1 |
| Coons, JC; Kido, K | 1 |
| Kelder, JC; Mager, JJ; Post, MC; Snijder, RJ; Ten Klooster, L; van Thor, MCJ | 1 |
| Locatelli, I; Petrovič, M | 1 |
| Amiya, E; Asano, Y; Hatano, M; Komuro, I; Kubota, K; Maki, H; Minatsuki, S; Morita, H; Sato, S; Yoshizaki, A | 1 |
| Sakao, S | 1 |
| Alehan, D; Aykan, H; Aypar, E; Ertugrul, İ; Karagöz, T | 1 |
| Amiya, E; Hara, T; Hatano, M; Hosoya, Y; Inaba, T; Kinugawa, K; Komuro, I; Maki, H; Minatsuki, S; Morita, H; Saito, A; Tsuji, M; Yao, A | 1 |
| Kam, CW; Ruiz, FE | 1 |
| Aleevskaya, AM; Martynyuk, TV | 1 |
| Ceriani, F; Cosentino, M; De Ponti, R; Ferrari, M; Imporzani, A; Lattanzio, M; Marino, F; Martini, S | 1 |
| Ekhlasi, M; Majd, ZK; Peiravian, F; Sheikhi, S; Yousefi, N | 1 |
| Amann, U; Haug, U; Kollhorst, B | 1 |
10 review(s) available for bosentan anhydrous and macitentan
| Article | Year |
|---|---|
From bosentan (Tracleer®) to macitentan (Opsumit®): The medicinal chemistry perspective.
Topics: Bosentan; Chemistry, Pharmaceutical; Dose-Response Relationship, Drug; Humans; Molecular Structure; Pyrimidines; Receptors, Endothelin; Structure-Activity Relationship; Sulfonamides | 2016 |
[Pharmacological treatment of pulmonary hypertension at a turning point].
Topics: Administration, Oral; Adult; Antihypertensive Agents; Bosentan; Carbolines; Endothelin Receptor Antagonists; Epoprostenol; Female; Humans; Hypertension, Pulmonary; Infusions, Intravenous; Male; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Piperazines; Pulmonary Artery; Purines; Pyridazines; Pyrimidines; Randomized Controlled Trials as Topic; Sildenafil Citrate; Sulfonamides; Sulfones; Tadalafil; Vascular Resistance; Vasodilator Agents | 2014 |
Endothelin@25 - new agonists, antagonists, inhibitors and emerging research frontiers: IUPHAR Review 12.
Topics: Antineoplastic Agents; Aspartic Acid Endopeptidases; Benzazepines; Bosentan; Endothelin A Receptor Antagonists; Endothelin-1; Endothelin-2; Endothelin-3; Endothelin-Converting Enzymes; Endothelins; Epigenesis, Genetic; Humans; Hypertension, Pulmonary; Metalloendopeptidases; Neoplasms; Peptide Fragments; Phenylpropionates; Pyridazines; Pyrimidines; Receptor, Endothelin B; Sulfonamides; Vasodilator Agents | 2014 |
Pharmacokinetic and pharmacodynamic evaluation of macitentan , a novel endothelin receptor antagonist for the treatment of pulmonary arterial hypertension.
Topics: Animals; Bosentan; Drug Interactions; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Humans; Hypertension, Pulmonary; Phenylpropionates; Pyridazines; Pyrimidines; Sulfonamides | 2015 |
Comparative safety and tolerability of endothelin receptor antagonists in pulmonary arterial hypertension.
Topics: Animals; Antihypertensive Agents; Bosentan; Chemical and Drug Induced Liver Injury; Drug Interactions; Drug Monitoring; Endothelin Receptor Antagonists; Heart Failure; Humans; Hypertension, Pulmonary; Phenylpropionates; Pyridazines; Pyrimidines; Risk; Sulfonamides | 2015 |
Drug Treatment of Idiopathic Pulmonary Fibrosis: Systematic Review and Network Meta-Analysis.
Topics: Acetylcysteine; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Azathioprine; Bayes Theorem; Bosentan; Endothelin Receptor Antagonists; Enzyme Inhibitors; Etanercept; Free Radical Scavengers; Humans; Idiopathic Pulmonary Fibrosis; Imatinib Mesylate; Immunosuppressive Agents; Indoles; Interferon-gamma; Phenylpropionates; Pyridazines; Pyridones; Pyrimidines; Recombinant Proteins; Sulfonamides; Vital Capacity; Warfarin | 2016 |
What is the position of pulmonary arterial hypertension-specific drug therapy in patients with Eisenmenger syndrome: A systematic review and meta-analysis.
Topics: Antihypertensive Agents; Bosentan; Eisenmenger Complex; Endothelin Receptor Antagonists; Exercise Tolerance; Hemodynamics; Humans; Hypertension, Pulmonary; Oxygen; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Prostaglandins; Pyridazines; Pyrimidines; Sulfonamides | 2019 |
Efficacy and Safety of the Use of Pulmonary Arterial Hypertension Pharmacotherapy in Patients with Pulmonary Hypertension Secondary to Left Heart Disease: A Systematic Review.
Topics: Bosentan; Endothelin Receptor Antagonists; Heart Diseases; Hemodynamics; Humans; Pulmonary Arterial Hypertension; Pyrazoles; Pyrimidines; Sildenafil Citrate; Sulfonamides | 2019 |
A Bayesian Network Meta-analysis of Add-on Drug Therapies Specific for Pulmonary Arterial Hypertension.
Topics: Adult; Antihypertensive Agents; Bayes Theorem; Bosentan; Drug Therapy, Combination; Endothelin Receptor Antagonists; Epoprostenol; Humans; Male; Network Meta-Analysis; Phosphodiesterase 5 Inhibitors; Practice Guidelines as Topic; Pulmonary Arterial Hypertension; Pyrimidines; Sulfonamides; Treatment Outcome | 2020 |
Opportunities and challenges of pharmacotherapy for pulmonary arterial hypertension in children.
Topics: Adolescent; Adult; Bosentan; Calcium Channel Blockers; Child; Child, Preschool; Epoprostenol; Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Iloprost; Infant; Infant, Newborn; Phenotype; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Prognosis; Pulmonary Arterial Hypertension; Pyridazines; Pyrimidines; Receptors, Endothelin; Sildenafil Citrate; Sulfonamides; Tadalafil; Young Adult | 2021 |
1 trial(s) available for bosentan anhydrous and macitentan
| Article | Year |
|---|---|
Macitentan does not interfere with hepatic bile salt transport.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Bosentan; Cell Line; Cricetinae; Dogs; Dose-Response Relationship, Drug; Endothelin Receptor Antagonists; Hepatocytes; Humans; Liver; Male; Organic Anion Transporters; Organic Anion Transporters, Sodium-Dependent; Pyrimidines; Rats; Sulfonamides; Symporters | 2014 |
28 other study(ies) available for bosentan anhydrous and macitentan
| Article | Year |
|---|---|
The discovery of N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-propylsulfamide (Macitentan), an orally active, potent dual endothelin receptor antagonist.
Topics: Administration, Oral; Animals; Antihypertensive Agents; CHO Cells; Cricetinae; Cricetulus; Drug Discovery; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Pyrimidines; Rats; Rats, Inbred Dahl; Sulfonamides | 2012 |
Design, synthesis and biological evaluation of benzamide derivatives as novel NTCP inhibitors that induce apoptosis in HepG2 cells.
Topics: Antineoplastic Agents; Antiviral Agents; Apoptosis; Benzamides; Drug Design; Hep G2 Cells; Hepatitis B; Hepatitis B virus; Humans; Molecular Docking Simulation; Organic Anion Transporters, Sodium-Dependent; Symporters; Virus Internalization | 2019 |
Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cells.
Topics: Animals; Bosentan; Calcium; CHO Cells; Clinical Trials, Phase III as Topic; Cricetinae; Endothelin Receptor Antagonists; Endothelin-1; Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Inositol Phosphates; Myocytes, Smooth Muscle; Phenylpropionates; Pulmonary Artery; Pyridazines; Pyrimidines; Receptors, Endothelin; Sulfonamides | 2012 |
Idiopathic pulmonary arterial hypertension.
Topics: Aminorex; Antihypertensive Agents; Appetite Depressants; Bosentan; Dasatinib; Epoprostenol; Familial Primary Pulmonary Hypertension; Fenfluramine; Genetic Predisposition to Disease; Humans; Hypertension, Pulmonary; Iloprost; Phenylpropionates; Piperazines; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyridazines; Pyrimidines; Risk Factors; Sildenafil Citrate; Sulfonamides; Sulfones; Thiazoles; Vasodilator Agents | 2013 |
Evaluation of the endothelin receptor antagonists ambrisentan, bosentan, macitentan, and sitaxsentan as hepatobiliary transporter inhibitors and substrates in sandwich-cultured human hepatocytes.
Topics: Adult; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Bile; Bile Acids and Salts; Bosentan; Endothelin Receptor Antagonists; Female; Hepatocytes; Humans; Isoxazoles; Liver; Liver-Specific Organic Anion Transporter 1; Male; Membrane Transport Proteins; Middle Aged; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Organic Anion Transporters; Organic Anion Transporters, Sodium-Dependent; Organic Anion Transporters, Sodium-Independent; Phenylpropionates; Pyridazines; Pyrimidines; Receptors, Endothelin; Solute Carrier Organic Anion Transporter Family Member 1B3; Sulfonamides; Symporters; Taurocholic Acid; Thiophenes | 2014 |
Comparison of pharmacological activity of macitentan and bosentan in preclinical models of systemic and pulmonary hypertension.
Topics: Animals; Bleomycin; Bosentan; Disease Models, Animal; Dose-Response Relationship, Drug; Endothelin Receptor Antagonists; Hypertension, Pulmonary; Pyrimidines; Rats; Rats, Inbred Dahl; Reproducibility of Results; Sulfonamides | 2014 |
Combinatorial targeting of early pathways profoundly inhibits neurodegeneration in a mouse model of glaucoma.
Topics: Animals; Astrocytes; Bosentan; Complement C1q; Disease Models, Animal; Endothelial Cells; Endothelin A Receptor Antagonists; Endothelin-2; Glaucoma; Humans; Mice; Mice, Inbred DBA; Nerve Degeneration; Pyrimidines; Receptor, Endothelin A; Retinal Ganglion Cells; Sulfonamides | 2014 |
Distinct ETA receptor binding mode of macitentan as determined by site directed mutagenesis.
Topics: Binding Sites; Bosentan; Catalytic Domain; Cell Line; Endothelin Receptor Antagonists; Humans; Inhibitory Concentration 50; Kinetics; Models, Molecular; Molecular Structure; Mutagenesis, Site-Directed; Mutation; Protein Binding; Protein Conformation; Pyrimidines; Receptors, Endothelin; Sulfonamides | 2014 |
Effects of macitentan and its active metabolite on cultured human systemic sclerosis and control skin fibroblasts.
Topics: Actins; Aged; Bosentan; Down-Regulation; Endothelin A Receptor Antagonists; Female; Fibroblasts; Humans; Male; Middle Aged; Pyrimidines; Scleroderma, Systemic; Skin; Sulfonamides | 2015 |
Comparison of Macitentan and Bosentan on Right Ventricular Remodeling in a Rat Model of Non-vasoreactive Pulmonary Hypertension.
Topics: Animals; Bleomycin; Bosentan; Disease Models, Animal; Endothelin Receptor Antagonists; Gene Expression Regulation; Heart Ventricles; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Male; Pulmonary Artery; Pyrimidines; Rats, Wistar; Sulfonamides; Time Factors; Vascular Remodeling; Ventricular Function, Right; Ventricular Remodeling | 2015 |
Bosentan and macitentan prevent the endothelial-to-mesenchymal transition (EndoMT) in systemic sclerosis: in vitro study.
Topics: Adult; Aged; Blotting, Western; Bosentan; Cell Transdifferentiation; Cells, Cultured; Coculture Techniques; Endothelial Cells; Endothelin Receptor Antagonists; Female; Fibroblasts; Humans; In Vitro Techniques; Middle Aged; Myofibroblasts; Pyrimidines; Real-Time Polymerase Chain Reaction; Scleroderma, Systemic; Sulfonamides | 2016 |
From bosentan to macitentan for pulmonary arterial hypertension and adult congenital heart disease: Further improvement?
Topics: Adult; Antihypertensive Agents; Bosentan; Cohort Studies; Drug Substitution; Female; Follow-Up Studies; Heart Defects, Congenital; Humans; Hypertension, Pulmonary; Male; Middle Aged; Prospective Studies; Pyrimidines; Sulfonamides | 2017 |
Functional estimation of endothelin-1 receptor antagonism by bosentan, macitentan and ambrisentan in human pulmonary and radial arteries in vitro.
Topics: Bosentan; Dose-Response Relationship, Drug; Endothelin Receptor Antagonists; Endothelin-1; Humans; Hypertension, Pulmonary; Phenylpropionates; Pulmonary Artery; Pyridazines; Pyrimidines; Radial Artery; Receptor, Endothelin A; Sulfonamides; Tissue Survival; Vasoconstriction | 2017 |
Plasma Drug Concentrations in Patients with Pulmonary Arterial Hypertension on Combination Treatment.
Topics: Adult; Aged; Bosentan; Case-Control Studies; Drug Interactions; Drug Therapy, Combination; Endothelin Receptor Antagonists; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Pyridazines; Pyrimidines; Sildenafil Citrate; Sulfonamides; Tadalafil | 2017 |
Clinical efficacy and safety of switch from bosentan to macitentan in children and young adults with pulmonary arterial hypertension.
Topics: Administration, Oral; Adolescent; Adult; Antihypertensive Agents; Bosentan; Child; Dose-Response Relationship, Drug; Endothelin A Receptor Antagonists; Female; Humans; Hypertension, Pulmonary; Male; Prospective Studies; Pulmonary Wedge Pressure; Pyrimidines; Sulfonamides; Treatment Outcome; Young Adult | 2018 |
Endothelin-1 receptor antagonists protect the kidney against the nephrotoxicity induced by cyclosporine-A in normotensive and hypertensive rats.
Topics: Acute Kidney Injury; Animals; Bosentan; Creatinine; Cyclosporine; Endothelin A Receptor Antagonists; Hemodynamics; Immunoblotting; Immunohistochemistry; Immunosuppressive Agents; Kidney; Male; Oxidative Stress; Protective Agents; Pyrimidines; Rats, Inbred SHR; Rats, Wistar; Reproducibility of Results; Sulfonamides; Treatment Outcome; Urea | 2017 |
German Guideline for Idiopathic Pulmonary Fibrosis - Update on Pharmacological Therapies 2017.
Topics: Acetylcysteine; Adult; Aged; Aged, 80 and over; Antacids; Bosentan; Clinical Trials as Topic; Evidence-Based Medicine; Female; Gastroesophageal Reflux; Guideline Adherence; Humans; Idiopathic Pulmonary Fibrosis; Imatinib Mesylate; Indoles; Male; Middle Aged; Phenylpropionates; Pyridazines; Pyridones; Pyrimidines; Sildenafil Citrate; Sulfonamides | 2018 |
Safety and feasibility audit of a home-based drug-transitioning approach for patients with pulmonary arterial hypertension: an observational study.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Phenylpropionates; Pyridazines; Pyrimidines; Retrospective Studies; Sulfonamides; Treatment Outcome | 2018 |
Choice of Initial Oral Therapy for Pulmonary Arterial Hypertension: Age and Long-Term Survival.
Topics: Administration, Oral; Age Factors; Bosentan; Drug Therapy, Combination; Endothelin Receptor Antagonists; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Pyridazines; Pyrimidines; Retrospective Studies; Sildenafil Citrate; Sulfonamides; Tadalafil | 2018 |
Bosentan or Macitentan Therapy in Chronic Thromboembolic Pulmonary Hypertension?
Topics: Aged; Bosentan; Chronic Disease; Drug Therapy, Combination; Endarterectomy; Endothelin Receptor Antagonists; Enzyme Activators; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Phosphodiesterase 5 Inhibitors; Pulmonary Embolism; Pyrazoles; Pyrimidines; Retrospective Studies; Sildenafil Citrate; Sulfonamides; Survival Rate; Walk Test | 2019 |
Characteristics of Pulmonary Arterial Hypertension in Patients with Systemic Sclerosis and Anticentriole Autoantibodies.
Topics: Aged; Aged, 80 and over; Antibodies, Antinuclear; Autoantibodies; Bosentan; Cardiac Catheterization; Centrioles; Drug Therapy, Combination; Endothelin Receptor Antagonists; Epoprostenol; Female; Forced Expiratory Volume; Humans; Imatinib Mesylate; Protein Kinase Inhibitors; Pulmonary Arterial Hypertension; Pulmonary Diffusing Capacity; Pyrimidines; Scleroderma, Systemic; Sildenafil Citrate; Sulfonamides; Tadalafil; Tomography, X-Ray Computed; Vasodilator Agents | 2020 |
Chronic lung disease-associated PH: PAH-approved drugs and established universal healthcare insurance in Japan.
Topics: Bosentan; Humans; Hypertension, Pulmonary; Idiopathic Pulmonary Fibrosis; Insurance Coverage; Japan; Phenylpropionates; Prevalence; Prognosis; Pulmonary Disease, Chronic Obstructive; Pyrazoles; Pyridazines; Pyrimidines; Sildenafil Citrate; Sulfonamides; Treatment Outcome; Universal Health Insurance | 2020 |
Clinical efficacy and safety of switch from bosentan to macitentan in children and young adults with pulmonary arterial hypertension: extended study results.
Topics: Administration, Oral; Adolescent; Adult; Antihypertensive Agents; Bosentan; Child; Endothelin A Receptor Antagonists; Female; Humans; Male; Prospective Studies; Pulmonary Arterial Hypertension; Pyrimidines; Sulfonamides; Time Factors; Treatment Outcome; Walk Test; Young Adult | 2020 |
The Clinical Efficacy of Endothelin Receptor Antagonists in Patients with Pulmonary Arterial Hypertension.
Topics: Administration, Oral; Adult; Aged; Bosentan; Case-Control Studies; Endothelin Receptor Antagonists; Female; Hemodynamics; Humans; Japan; Male; Middle Aged; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Placebos; Prostaglandins I; Pulmonary Arterial Hypertension; Pulmonary Wedge Pressure; Pyridazines; Pyrimidines; Retrospective Studies; Sulfonamides; Treatment Outcome; Vascular Resistance | 2020 |
[Dynamics of the clinical functional and hemodynamic profile of patients with pulmonary arterial hypertension with initial monotherapy with endothelin receptor antagonists: bosentan vs. macitentan].
Topics: Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Familial Primary Pulmonary Hypertension; Hemodynamics; Humans; Hypertension, Pulmonary; Pulmonary Arterial Hypertension; Pyrimidines; Retrospective Studies; Russia; Sulfonamides; Treatment Outcome | 2020 |
Pharmacological counseling in hepatotoxicity induced by macitentan and selexipag: a case report.
Topics: Bosentan; Counseling; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP2C9; Endothelin Receptor Antagonists; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Middle Aged; Pulmonary Arterial Hypertension; Receptors, Epoprostenol; Transaminases | 2022 |
Cost-Effectiveness Analysis of Macitentan in Comparison With Bosentan in the Treatment of Pulmonary Arterial Hypertension in Iran.
Topics: Bosentan; Cost-Effectiveness Analysis; Humans; Hypertension, Pulmonary; Iran; Pulmonary Arterial Hypertension; Quality of Life | 2023 |
Prescribing of endothelin receptor antagonists and riociguat in women of childbearing age in a large German claims database study.
Topics: Animals; Bosentan; Cross-Sectional Studies; Endothelin Receptor Antagonists; Female; Hypertension, Pulmonary | 2023 |